(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 53.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Axsome Therapeutics's revenue in 2025 is $385,693,000.On average, 9 Wall Street analysts forecast AXSM's revenue for 2025 to be $30,060,018,483, with the lowest AXSM revenue forecast at $27,629,502,032, and the highest AXSM revenue forecast at $32,575,289,204. On average, 9 Wall Street analysts forecast AXSM's revenue for 2026 to be $46,952,110,255, with the lowest AXSM revenue forecast at $38,044,816,804, and the highest AXSM revenue forecast at $61,766,259,440.
In 2027, AXSM is forecast to generate $69,166,311,814 in revenue, with the lowest revenue forecast at $57,026,262,268 and the highest revenue forecast at $88,593,082,938.